.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,988,974

« Back to Dashboard

Details for Patent: 7,988,974

Title:Antifusogenic proteins comprising human immunodeficiency virus type 1 (HIV-1) gp41 DP-178 polypeptide variants and a macromolecular carrier
Abstract: The present invention relates to fusion peptides which exhibit potent anti-retroviral activity. The fusion peptides of the invention comprise a macromolecular carrier group fused to a gp41-derived DP178 (SEQ ID NO:1) peptide corresponding to amino acids 638 to 673 of the HIV-1.sub.LA1 gp41 protein, or fragments, analogs or homologs of DP178. The invention further relates to the uses of such fusion peptides as inhibitory of human and non-human retroviral, especially HIV, transmission to uninfected cells.
Inventor(s): Greenberg; Michael L. (Chapel Hill, NC), Matthews; Thomas James (Henderson, NC), Chen; Chin-Ho (Chapel Hill, NC)
Assignee: Duke University (Durham, NC)
Filing Date:Oct 17, 2005
Application Number:11/253,274
Claims:1. A fusion protein comprising a macromolecular carrier group fused to a gp41 polypeptide variant, wherein: (a) the macromolecular carrier group comprises a peptide group; and (b) the gp41 polypeptide variant has an amino acid sequence of residues 621-678 of HIV-1 gp41 wherein said numbering scheme is based upon the isolate HIV-1.sub.BRU, further has from 1 to 22 contiguous amino acids truncated from its carboxy terminus, and wherein said variant does not consist of SEQ ID NO:893 and wherein said variant is obtained from an HIV-1 isolate other than HIV-1.sub.LA1; and wherein the fusion protein exhibits anti-HIV activity.

2. The fusion protein of claim 1, wherein said gp41 polypeptide variant further has 1 to 22 contiguous amino acids truncated from its amino terminus and said variant does not consist of T660 (SEQ ID NO. 894); T659 (SEQ ID NO. 895); T658 (SEQ ID NO. 896); T657 (SEQ ID NO. 897); T656 (SEQ ID NO. 898); T655 (SEQ ID NO. 899); T654 (SEQ ID NO. 900); T653 (SEQ ID NO. 901); T652 (SEQ ID NO. 902); T651 (SEQ ID NO. 903); T625 (SEQ ID NO. 904); T650 (SEQ ID NO. 905); T649 (SEQ ID NO. 906); T624 (SEQ ID NO. 907); T50 (SEQ ID NO. 908); T648 (SEQ ID NO. 909); T647 (SEQ ID NO. 910); T711 (SEQ ID NO. 911); T621 (SEQ ID NO. 912); T646 (SEQ ID NO. 913); T645 (SEQ ID NO. 914); T644 (SEQ ID NO. 915); T643 (SEQ ID NO. 916); T642 (SEQ ID NO. 917); T622 (SEQ ID NO. 918); T623 (SEQ ID NO. 919); T51 (SEQ ID NO. 920), T641 (SEQ ID NO. 921); T640 (SEQ ID NO. 922); or T20 (SEQ ID NO. 1).

3. A fusion protein comprising a macromolecular carrier group fused to a gp41 polypeptide variant, wherein: (a) the macromolecular carrier group comprises a peptide group; and (b) the gp41 polypeptide variant has an amino acid sequence of residues 643-691 of HIV-1 gp41 wherein said numbering scheme is based upon the isolate HIV-1.sub.BRU, and further has from 1 to 7 contiguous amino acids truncated from its amino terminus, wherein said variant is obtained from an HIV-1 isolate other than HIV-1.sub.LA1; and wherein the fusion protein exhibits anti-HIV activity.

4. A fusion protein comprising a macromolecular carrier group fused to a gp41 polypeptide variant, wherein: (a) the macromolecular carrier group comprises a peptide group; and (b) the gp41 polypeptide variant has an amino acid sequence of residues 643-691 of HIV-1 gp41, wherein said numbering scheme is based upon the isolate HIV-1.sub.BRU, further has from 1 to 13 contiguous amino acids truncated from its carboxy terminus, and wherein said gp41 polypeptide variant further has 1 to 7 contiguous amino acids truncated from its amino terminus wherein said variant does not consist of SEQ ID NO:1, T20 (SEQ ID NO. 1); T639 (SEQ ID NO. 925); T638 (SEQ ID NO. 926); T637 (SEQ ID NO. 927); T636 (SEQ ID NO. 928); T635 (SEQ ID NO. 929); T634 (SEQ ID NO. 930); or T633 (SEQ ID NO. 931), and wherein said variant is obtained from an HIV-1 isolate other than HIV-1.sub.LA1; and wherein the fusion protein exhibits anti-HIV activity.

5. A recombinant vector comprising a nucleic acid molecule encoding the fusion protein of claim 1, 2, 3 or 4.

6. The fusion protein of claim 1, 2, 3 or 4, wherein the peptide is an oligopeptide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc